Testing a new drug combo before surgery for liver cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests if combining three therapies (sintilimab, lenvatinib, and HAIC) before surgery can help shrink liver tumors that are on the borderline of being removable. It's for people whose cancer has spread into nearby blood vessels but not to other organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- Your liver cancer must have grown into the main blood vessels but not spread to other parts of the body.
- You cannot have had any prior cancer treatment, and your doctor believes the tumor might be removable with surgery.
- Your liver function must be good enough (Child-Pugh score A or B).
- You must have a tumor that can be measured on a scan.
- You must be willing to use effective birth control during and for a few months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining the immunotherapy drug sintilimab with targeted radiation therapy before surgery can improve outcomes for patients with liver cancer that can be surgically removed. It aims to shrink the tumor and reduce the chance of recurrence.
This trial tests a treatment given before surgery to shrink liver cancer and improve outcomes. It combines a liver-directed therapy (HAIC) with two oral drugs (lenvatinib and a PD-1 inhibitor) for people with intermediate-stage liver cancer that can be removed surgically.
This trial tests a combination of liver-directed chemotherapy (HAIC), two immunotherapy drugs (iparomlimab and tuvonralimab), and bevacizumab (a drug that blocks blood vessel growth) in people with liver cancer that is too large or numerous for immediate surgery but might become removable after treatment. The goal is to shrink the tumor enough to allow surgery.
This trial tests a new precision approach for people with liver cancer that cannot be removed by surgery. It uses a computer model to analyze your tumor and genetic information to see if combining HAIC (chemotherapy directly into the liver), lenvatinib (a targeted drug), and a PD-1 inhibitor (immunotherapy) is the right treatment for you.
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
This trial tests whether a combination of two drugs (tislelizumab and lenvatinib) given before surgery can lower the risk of liver cancer coming back in people with early-stage but high-risk disease.
Hear when a new HCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.